Article

February 11, 2015

Confirmed: Valeant to Buy Dendreon

Following reports last week of a bid, it has now been confirmed that the Canadian company Valeant Pharmaceuticals International Inc will buy Provenge-maker Dendreon.

Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp, after no additional qualified bids came forward by Tuesday's deadline, Valeant said.

A potential buyer dropped from the bidding process, three sources close to the sale told Reuters earlier.

Valeant, of Laval, Quebec, will get Seattle-based Dendreon's Provenge cancer treatment and other assets for $400 million in cash.

Complete news on Reuters: http://reut.rs/17hWY2r

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

CK Wang, MD, COTA

Eric Lander, MD

Eric Lander, MD

David Awad, PharmD, BCOP

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center

Coral Omene, MD, PhD, sitting for a vieo interview

David Awad, PharmD, BCOP

Coral Omene, MD, PhD, sitting for a vieo interview

Related Content

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

David Nguyen, MD | Image Credit: Tufts Medicine

July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

July 23rd 2025

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

AJMC Contributor

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Christine Pfaff, MBA, RPh | Image: LinkedIn

July 22nd 2025

COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

Christine Pfaff, MBA, RPh, joins COA as director of clinical initiatives, enhancing support for community oncology practices and pharmacy operations amid health care challenges.

Related Content

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

Midkine May Play Key Role in SCLC

Jared Kaltwasser

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

Managed Care Cast

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

David Nguyen, MD | Image Credit: Tufts Medicine

July 23rd 2025

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

Maggie L. Shaw David Nguyen, MD

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

July 23rd 2025

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

AJMC Contributor

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Christine Pfaff, MBA, RPh | Image: LinkedIn

July 22nd 2025

COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

Christine Pfaff, MBA, RPh, joins COA as director of clinical initiatives, enhancing support for community oncology practices and pharmacy operations amid health care challenges.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions